These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 37118682

  • 1. Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series.
    Kaltseis K, Filippi V, Frank F, Eckhardt C, Schiefecker A, Broessner G.
    BMC Neurol; 2023 Apr 28; 23(1):174. PubMed ID: 37118682
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.
    Scheffler A, Wenzel P, Bendig M, Gendolla A, Basten J, Kleinschnitz C, Nsaka M, Lindner D, Naegel S, Burow P, Fleischmann R, Holle D.
    J Headache Pain; 2024 May 16; 25(1):79. PubMed ID: 38755541
    [Abstract] [Full Text] [Related]

  • 3. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.
    Straube A, Broessner G, Gaul C, Hamann X, Hipp J, Kraya T, Neeb L.
    J Headache Pain; 2023 May 23; 24(1):59. PubMed ID: 37221478
    [Abstract] [Full Text] [Related]

  • 4. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience.
    Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U.
    J Headache Pain; 2023 Feb 27; 24(1):16. PubMed ID: 36843007
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan.
    Wang YF, Yang FC, Chen LA, Chang TY, Su HC, Yang CP, Tu YH, Tzeng YS, Chen SP, Fuh JL, Lai KL, Ling YH, Chen WT, Wang SJ.
    Eur J Neurol; 2024 Sep 27; 31(9):e16372. PubMed ID: 38837528
    [Abstract] [Full Text] [Related]

  • 6. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, Ahmad L, Corrado M, Bighiani F, Tanganelli F, Bottiroli S, Cammarota F, Sances G, Tassorelli C.
    J Headache Pain; 2022 Sep 17; 23(1):123. PubMed ID: 36115947
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y, Hirata K.
    Cephalalgia; 2023 May 17; 43(5):3331024231177649. PubMed ID: 37231663
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d'Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C.
    J Headache Pain; 2021 Dec 18; 22(1):154. PubMed ID: 34922444
    [Abstract] [Full Text] [Related]

  • 13. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U.
    CNS Drugs; 2021 Aug 18; 35(8):805-820. PubMed ID: 34272688
    [Abstract] [Full Text] [Related]

  • 14. Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand.
    Anukoolwittaya P, Hiransuthikul A, Pongpitakmetha T, Thanprasertsuk S, Rattanawong W.
    J Headache Pain; 2024 Sep 12; 25(1):150. PubMed ID: 39267011
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series.
    Briceño-Casado MDP, Gil-Sierra MD, De-La-Calle-Riaguas B.
    Eur J Hosp Pharm; 2023 Jul 12; 30(4):e19. PubMed ID: 34521726
    [Abstract] [Full Text] [Related]

  • 17. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
    Overeem LH, Lange KS, Fitzek MP, Siebert A, Steinicke M, Triller P, Hong JB, Reuter U, Raffaelli B.
    Front Neurol; 2023 Jul 12; 14():1154420. PubMed ID: 37034092
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
    Barbanti P, Aurilia C, Egeo G, Proietti S, Torelli P, d'Onofrio F, Carnevale A, Tavani S, Orlando B, Fiorentini G, Colombo B, Filippi M, Bonassi S, Cevoli S, Italian Migraine Registry (I-GRAINE) study group.
    J Neurol; 2024 May 12; 271(5):2605-2614. PubMed ID: 38342785
    [Abstract] [Full Text] [Related]

  • 20. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.
    Headache; 2020 Sep 12; 60(8):1734-1742. PubMed ID: 32799325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.